Merck, 176905-100UG, Anthrax Protective Antigen, Bacillus anthracis, Recombinant, B. anthracis

General description
Recombinant, Bacillus anthracis anthrax protective antigen expressed in a special strain of B. anthracis. One of three protein components of anthrax toxin produced by the pathogenic bacterium, Bacillus anthracis. Central moiety that mediates entry of lethal factor (LF) and edema factor (EF) into the target cell. PA83 binds to the cell surface via a type I membrane receptor with a von Willebrand factor A domain, known as anthrax toxin receptor. PA83 is proteolytically activated in vivo by a furin-like protease to produce a 63 kDa protein (PA63). PA63 self-associates to form a heptameric, cation-selective, voltage-gated, membrane channel that subsequently binds to LF and/or EF. Cleavage of the 20 kDa fragment from PA83 is necessary for binding of protective antigen to LF and EF.
Biochem/physiol Actions
Cell permeable: no
Primary Target
Type I membrane protein with a von Willebrand factor A domain called anthrax toxin receptor
Product does not compete with ATP.
Reversible: no
Packaging
yes
Physical form
Lyophilized from 50 mM NaCl, 5 mM HEPES, pH 7.5.
Preparation Note
Following reconstitution aliquot and freeze (-20°C). Avoid freeze/thaw cycles of solutions. Stock solutions are stable for up to 6 months at -20°C.
Reconstitute in 100 µl sterile, distilled H₂O to yield a final concentration of 1 mg/ml.
Analysis Note
Single major band by SDS-PAGE. Several smaller minor components are apparent that may represent cleavage fragments of the PA.
Other Notes
Mogridge, J., et al. 2002. Biochemistry41, 1079.
Nassi, S., et al. 2002. Biochemistry41, 1445.
Ahuja, N., et al. 2001. Biochem. Biophys. Res. Commun.286, 6.
Bradley, K.A., et al. 2001. Nature414, 225.
Brossier, F., and Mock, M. 2001. Toxicon39, 1747.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)